➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Baxter
Johnson and Johnson

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,016,404

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,016,404
Title:Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Abstract: The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
Inventor(s): Rader; Daniel J. (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:15/605,548
Patent Claims: 1. A method of treating a human subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the human subject an effective amount of an MTP inhibitor, the administration of the MTP inhibitor comprising three step-wise, increasing dose levels of the MTP inhibitor, wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4' (trifluoromethyl)[1,1'-biphenyl]-2-yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9 carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor reduces total cholesterol of the human subject by at least 30% as compared to control blood levels.

2. The method of claim 1, wherein the human subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia.

3. The method of claim 1, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level.

4. The method of claim 1, wherein the administration of the MTP inhibitor reduces non-high- density lipoprotein cholesterol of the human subject by at least 30% as compared to control blood levels.

5. The method of claim 1, wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a human subject at a starting dose of 25 mg/day.

6. The method of claim 5, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in liver transaminases, an increase in hepatic fat, or a combination thereof.

7. A method of treating a human subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the human subject an effective amount of an MTP inhibitor, the administration of the MTP inhibitor comprising three step-wise, increasing dose levels of the MTP inhibitor, wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4' (trifluoromethyl)[1,1'-biphenyl]-2-yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9 carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a human subject at a starting dose of 25 mg/day.

8. The method of claim 7, wherein the human subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia.

9. The method of claim 7, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level.

10. The method of claim 7, wherein the administration of the MTP inhibitor reduces non-high- density lipoprotein cholesterol of the human subject by at least 30% as compared to control blood levels.

11. The method of claim 7, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in liver transaminases, an increase in hepatic fat, or a combination thereof.

12. The method of claim 11, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in hepatic fat.

13. The method of claim 12, wherein the increase in hepatic fat is not greater than 37% from baseline.

14. A method of treating a human subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the human subject an effective amount of an MTP inhibitor, the administration of the MTP inhibitor comprising three step-wise, increasing dose levels of the MTP inhibitor, wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the first dose level is sub-therapeutic; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4' (trifluoromethyl)[1,1'-biphenyl]-2-yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9 carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor reduces total cholesterol of the human subject by at least 30% as compared to control blood levels.

15. The method of claim 14, wherein the human subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia.

16. The method of claim 14, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level.

17. The method of claim 14, wherein the administration of the MTP inhibitor reduces non-high- density lipoprotein cholesterol of the human subject by at least 30% as compared to control blood levels.

18. The method of claim 14, wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a human subject at a starting dose of 25 mg/day.

19. The method of claim 18, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in liver transaminases, an increase in hepatic fat, or a combination thereof.

20. A method of treating a human subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the human subject an effective amount of an MTP inhibitor, the administration of the MTP inhibitor comprising three step-wise, increasing dose levels of the MTP inhibitor, wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the first dose level is sub-therapeutic; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4' (trifluoromethyl)[1,1'-biphenyl]-2-yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9 carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a human subject at a starting dose of 25 mg/day.

21. The method of claim 20, wherein the human subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia.

22. The method of claim 20, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level.

23. The method of claim 20, wherein the administration of the MTP inhibitor reduces non-high- density lipoprotein cholesterol of the human subject by at least 30% as compared to control blood levels.

24. The method of claim 20, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in liver transaminases, an increase in hepatic fat, or a combination thereof.

25. The method of claim 24, wherein the side effects minimized by the administration of the MTP inhibitor comprise an increase in hepatic fat.

26. The method of claim 25, wherein the increase in hepatic fat is not greater than 37% from baseline.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
McKesson
Dow
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.